Irinotecan Sun

Irinotecan, the active ingredient in Irinotecan Sun, is a topoisomerase I inhibitor presented as an intravenous solution for intravenous administration. It is used in the treatment of metastatic and advanced colorectal cancer in adult patients, where it forms part of standard chemotherapy regimens.

GNH USA supplies Irinotecan Sun as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to oncology centres, hospitals and pharmacies worldwide while ensuring reliable, on‑time delivery and regulatory compliance.

Irinotecan is a topoisomerase I inhibitor used in colorectal cancer therapy.

Metastatic colorectal cancer: improves overall survival when combined with fluoropyrimidine‑based regimens. Advanced colorectal cancer: provides disease control in patients who have progressed after prior therapy. Colorectal cancer (in combination therapy): enhances response rates when used with other chemotherapeutic agents.

Irinotecan is associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Neutropenia: reduced white blood cell count increasing infection risk. - Diarrhea: often severe and may require antidiarrheal therapy. - Nausea and vomiting: typical chemotherapy‑related symptoms. - Fatigue: generalized tiredness affecting daily activities. - Alopecia: hair loss that is usually reversible. - Anemia: decreased red blood cell count causing fatigue.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophils requiring urgent care. - Severe colitis: life‑threatening inflammation of the colon. - Hepatic toxicity: elevated liver enzymes or jaundice. - Severe allergic reactions: anaphylaxis or hypersensitivity. - Stomatitis: painful inflammation of the mouth lining. - Cardiotoxicity: rare cardiac events such as arrhythmias.

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor for toxicity.

Monitor blood counts: perform regular CBC to detect neutropenia. Assess liver function: adjust dosing in hepatic impairment. Hydration: maintain adequate fluid intake to reduce risk of severe diarrhea. Avoid concurrent myelosuppressive agents unless clinically necessary. Pregnancy and lactation: contraindicated unless benefits outweigh risks. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Irinotecan may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - UGT1A1 inhibitors (e.g., atazanavir): increase SN‑38 exposure – avoid. - Strong CYP3A4 inducers (e.g., rifampin): reduce efficacy – avoid. - Concurrent myelosuppressive chemotherapy: heightened bone‑marrow toxicity – avoid.

Moderate Interactions (Monitor Closely): - Antiemetics (e.g., ondansetron): may affect metabolism – monitor. - Warfarin: potential increased bleeding – monitor INR. - Fluoropyrimidines (e.g., 5‑FU): additive gastrointestinal toxicity – monitor.